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Abstract
Background: Disease modeling with patient-derived induced pluripotent stem cells (iPSCs) is a powerful tool for
elucidating the mechanisms underlying disease pathogenesis and developing safe and effective treatments. Patient
peripheral blood (PB) cells are used for iPSC generation in many cases since they can be collected with minimum
invasiveness. To derive iPSCs that lack immunoreceptor gene rearrangements, hematopoietic stem and progenitor
cells (HSPCs) are often targeted as the reprogramming source. However, the current protocols generally require
HSPC mobilization and/or ex vivo expansion owing to their sparsity at the steady state and low reprogramming
efficiencies, making the overall procedure costly, laborious, and time-consuming.
Methods: We have established a highly efficient method for generating iPSCs from non-mobilized PB-derived
CD34+ HSPCs. The source PB mononuclear cells were obtained from 1 healthy donor and 15 patients and were
kept frozen until the scheduled iPSC generation. CD34+ HSPC enrichment was done using immunomagnetic beads,
with no ex vivo expansion culture. To reprogram the CD34+-rich cells to pluripotency, the Sendai virus vector
SeVdp-302L was used to transfer four transcription factors: KLF4, OCT4, SOX2, and c-MYC. In this iPSC generation
series, the reprogramming efficiencies, success rates of iPSC line establishment, and progression time were
recorded. After generating the iPSC frozen stocks, the cell recovery and their residual transgenes, karyotypes, T cell
receptor gene rearrangement, pluripotency markers, and differentiation capability were examined.
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Results: We succeeded in establishing 223 iPSC lines with high reprogramming efficiencies from 15 patients with 8
different disease types. Our method allowed the rapid appearance of primary colonies (~ 8 days), all of which were
expandable under feeder-free conditions, enabling robust establishment steps with less workload. After thawing,
the established iPSC lines were verified to be pluripotency marker-positive and of non-T cell origin. A majority of
the iPSC lines were confirmed to be transgene-free, with normal karyotypes. Their trilineage differentiation
capability was also verified in a defined in vitro assay.
Conclusion: This robust and highly efficient method enables the rapid and cost-effective establishment of
transgene-free iPSC lines from a small volume of PB, thus facilitating the biobanking of patient-derived iPSCs and
their use for the modeling of various diseases.
Keywords: Human-induced pluripotent stem cells, Sendai virus vector, SeVdp-302L, Feeder-free, CD34+
hematopoietic stem and progenitor cells, Peripheral blood, Disease modeling, Biobank
Background
In the past decade, thousands of human-induced
pluripotent stem cells (hiPSCs) have been generated
from healthy donors and from patients afflicted with
various diseases [1–3]. The patient-derived hiPSCs have the
potential to infinitely produce specialized disease-associated
cells and organoids, enabling researchers to recapitulate
some pathological aspects in Petri dishes for human disease
modeling. In fact, such models have already contributed to
the uncovering of molecular mechanisms of pathogenesis,
potentially leading to the development of new treatments
for some diseases [3]. Therefore, a simple and efficient
method to establish patient-derived hiPSC lines in labora-
tories and biobanks is essential to facilitate the further un-
derstanding of disease pathogenesis and the development
of safe and effective treatments.
Although many different methods for generating hiPSCs
have been developed, they all have huge variations in their
characteristics, including efficiency, quality, speed, cost, and
robustness. Several non-integrating methods are currently
available, using episomal DNAs [4, 5], Sendai virus (SeV)
[6], adenovirus [7], PiggyBac transposons [8], minicircles
[9], synthesized RNAs [10], and recombinant proteins [11]
to transfer reprogramming factors into target cells. More-
over, many additional enhancers for somatic cell repro-
gramming have been identified and used with or without
these technologies [12]. However, these technologies gener-
ally remain inefficient overall, with their reprogramming
efficiencies being less than 1% in many cases [13–15]. An
unstable and/or insufficient transgene expression may be a
contributory factor. Prolonged residual exogenous factors
may also negatively affect the high-quality generation of
transgene-free hiPSCs [4, 6]. Recently, we reported the use
of a novel SeV vector, SeVdp-302L, which delivers a single-
stranded RNA genome containing multiple transgenes into
somatic cells in a manner suitable for hiPSC generation.
The SeVdp-302L vector carrying four Yamanaka fac-
tors, named SeVdp(KOSM)-302L, induces stable trans-
gene expression and also possesses an auto-erasable
feature by responding to the presence of stem cell-specific
microRNA-302. Using this vector, we demonstrated the
simple and efficient generation of transgene-free hiPSCs
without additional reprogramming enhancers [16].
Patient-derived hiPSCs are generated from various som-
atic cells, the two major sources of which are skin fibro-
blasts [1] and peripheral blood (PB) [17]. However, skin
fibroblasts require some invasive procedures for collection
and have a potential risk of accumulated mutations result-
ing from their exposure to external stressors, such as UV
rays. Indeed, undeniably high frequencies of preexisting
coding mutations have been identified in both the original
fibroblasts and their derived hiPSCs [18]. On the other
hand, PB is thought to be a more attractive somatic cell
source, since its collection is less invasive and its muta-
tional load is presumably lower than that of skin tissue.
PB is also considered useful for hiPSC generation because
the cells remain viable enough at room temperature for ~
48 h after collection [19] and after cryopreservation, enab-
ling long-distance transport of the patient samples and
scheduled hiPSC generation. For PB cell reprogramming,
either lymphocytes (mostly T cells) or non-lymphocytes
(e.g., stem and progenitor cells and myeloid cells) are used
to generate hiPSCs. The choice depends on the aim of the
studies, where lymphocytes are preferred when the spe-
cific immunoreceptor gene rearrangement is required,
whereas non-lymphocytes are used for broader applications.
Pioneering studies tested PB-derived CD34+ hematopoietic
stem and progenitor cells (HSPCs) as a source for generat-
ing non-lymphocyte-derived hiPSCs, resulting in the suc-
cessful establishment of such cells but with very low
reprogramming efficiencies [20, 21]. Other studies used
mobilized PB-derived CD34+ cells to obtain a sufficient
number of target cells [17, 22–25], but the mobilization
procedure was not suited to ill-conditioned patients in gen-
eral. For the use of non-mobilized PB cells, most studies
have conducted ex vivo expansion culture of the CD34+
HSPCs either in a way favoring general myeloid cell prolif-
eration or erythroid cell growth, mainly to overcome their
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scarcity at the steady state or to enhance their overall effi-
ciencies [19, 20, 26–37]. These cultures need a lot of cyto-
kines, making the procedures costly and labor-intensive.
Therefore, it is desirable to develop an hiPSC generation
protocol that allows the use of non-mobilized PB-derived
CD34+ cells without the need for extensive culturing, while
achieving high efficiency and robustness.
Previously, we had succeeded in generating disease-
specific hiPSCs from patient bone marrow-derived
CD34+ cells or from freshly obtained PB-derived CD34+
cells using the SeVdp vector (the one-generation-old ver-
sion of SeVdp-302L) with on-feeder conditions [38–40].
However, for the purpose of biobanking, we sought to es-
tablish a more robust method to fulfill the abovementioned
requirements and to allow a feeder-free protocol for sim-
plicity. Consequently, in this present paper, we report the
successful establishment of a series of hiPSC lines from 15
patients with 8 different types of diseases, using our new
protocol. This simple SeV method allows the robust and
rapid establishment of transgene-free hiPSC lines from
non-mobilized blood samples, with high reprogramming
efficiencies (up to > 5%). The scheduled hiPSC gener-
ation was feasible because we could start a CD34+ cell-
enrichment step from frozen mononuclear cell stocks
without hampering the overall establishment proce-
dures. No extensive expansion culture was necessary.
Characterization of the hiPSC lines verified their utility
for downstream applications, with their stable pluripo-
tency and intact trilineage differentiation capability.
Taken together, the results of this study indicate that
this robust and highly efficient method promises the fa-
cile establishment of disease-specific hiPSC lines that
are compatible with the purpose for biobanking, which
will be useful for medical research.
Methods
Preparation of healthy donor and patient PBMC samples
A frozen vial of PB mononuclear cells (PBMCs) derived
from a healthy donor was purchased from Lonza Walk-
ersville. The other PB samples described in this report
were obtained from 15 patients with 8 different diseases.
Informed consent was obtained in an appropriate man-
ner for all the cases according to the Declaration of
Helsinki standard ethics procedure, with approval from
the Institutional Ethical Committees (see “Ethics ap-
proval and consent to participate” section). The non-
mobilized fresh PB samples from patients were collected
into heparin tubes by venipuncture. Except for 2 cases, all
patient PBMCs were purified with Lymphocyte Separation
Medium (PromoCell) in 50-mL Leucosep™ Tubes (Greiner
Bio-One) within 5 h after PB collection and were then
cryopreserved in Bambanker™ freezing medium (NIPPON
Genetics) for up to ~ 1 year in liquid nitrogen until use
for hiPSC generation (Table 1). In the cases of patients for
TkSCR1 and TkS42-1, who resided far from Tokyo, the
purification and cryopreservation of their PBMCs were
performed on the next day after long-distance transport of
the samples to our laboratory.
Preparation of CD34+-enriched cell population
At day − 3, 0.4 × 107 to 1.0 × 107 PBMCs were thawed
with ThawSTAR™ (BioCision) and kept overnight in
Embryoid Body (EB) medium in 6-well plates at 37 °C
with 5% CO2 (Fig. 1a and Table 2). The EB medium con-
sisted of Iscove’s modified Dulbecco’s medium (Sigma)
supplemented with 15% fetal bovine serum (Nichirei Bio-
sciences), ITS liquid media supplement (Sigma), penicillin-
streptomycin-glutamine (Gibco), 50 μg/mL L-ascorbic acid
(Sigma), 0.45 mM 1-thioglycerol (Sigma), and the following
six cytokines: 50 ng/mL stem cell factor, 50 ng/mL Fms-
related tyrosine kinase 3 ligand, 10 ng/mL interleukin-3, 10
ng/mL interleukin-6, 50 ng/mL thrombopoietin, and 20
ng/mL granulocyte colony-stimulating factor (G-CSF) (all
from R&D Systems). At day − 2, enrichment of the CD34+
cells was performed using the CD34 MicroBead Kit
(Miltenyi Biotec) according to the manufacturer’s
instructions. The CD34+-enriched PBMCs were kept
Table 1 Information on the healthy donor and patient samples
Healthy donor and
patients (hiPSC line)
Age (year)/
gender
No. of cells or
blood volume
donated
No. of purified
PBMCs per 1 mL
blood sample
Healthy (TkPP2) 33/M 1.0 × 107 cells N.A.
SLE (TkSLE3) 59/F 22 mL 0.5 × 106 cells/mL
SLE (TkSLE4) 50/F 30 mL 0.5 × 106 cells/mL
SLE (TkSLE5) 43/F 30 mL 1.3 × 106 cells/mL
PM (TkSPD3) 65/M 30 mL 0.7 × 106 cells/mL
PM (TkSPD4) 45/F 30 mL 2.4 × 106 cells/mL
PM (TkSPD5) 56/M 30 mL 1.1 × 106 cells/mL
X-CGD (TkSCG3) 18/M 38 mL 0.8 × 106 cells/mL
X-CGD (TkSCG4) 9/F 20 mL 1.2 × 106 cells/mL
PID (TkSPR1) 33/F 30 mL 1.9 × 106 cells/mL
PID (TkSPR2) 30/F 22 mL 1.3 × 106 cells/mL
JIA (TkSCR1) 3/F 23 mL 2.4 × 106 cells/mL
CMS (TkS42–1) 11/F 26 mL 0.7 × 106 cells/mL
MD (TkSmD1) 59/M 40 mL 0.5 × 106 cells/mL
MD (TkSmD3) 32/M 30 mL 1.1 × 106 cells/mL
KCS2 (TkSKCII2) 13/F 22 mL 1.0 × 106 cells/mL
The disease/symptom affecting each individual and the name of the derived
human induced pluripotent stem cell (hiPSC) line are listed. The age and
gender of each donor are also indicated. The number (No.) of peripheral blood
mononuclear cells (PBMCs) and total peripheral blood (PB) volume donated
are shown for the purchased healthy donor PBMCs and the patient PBMCs,
respectively. The right-hand column shows the number of PBMCs purified
from 1 mL of patient PB
SLE systemic lupus erythematosus, PM polymyositis, X-CGD X-linked chronic
granulomatous disease, PID primary immunodeficiency, JIA juvenile idiopathic
arthritis, CMS congenital malformation syndrome, MD mitochondrial diabetes,
KCS2 Kenny-Caffey syndrome type 2, N.A not applicable
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overnight in EB medium in 96-well plates at 37 °C with
5% CO2 to ensure the recovery of truly viable cells for
the subsequent reprogramming procedures (Fig. 1a).
Analysis of enriched CD34+ cells derived from PBMCs
The purchased healthy donor PBMCs were kept over-
night in EB medium after thawing, following which
approximately three-quarters of the cells were sub-
jected to CD34+ cell enrichment as described above.
Both positively selected cells and a flow-through
population were obtained. The remaining one-quarter
of PBMCs was left untouched as the non-treated con-
trol sample. The three samples were stained with
allophycocyanin-conjugated anti-human CD34 antibody
(343510, BioLegend), Pacific Blue™ dye-conjugated anti-
human CD45 antibody (304022, BioLegend), and a fluor-
escein isothiocyanate-conjugated anti-human lineage
cocktail (CD3, CD14, CD19, CD20, and CD56) (348701,
BioLegend). The samples were also stained with propi-
dium iodide to exclude dead cells. Population data were
acquired with a fluorescence-activated cell sorting (FACS)
Aria II sorter (BD Biosciences) and analyzed using FlowJo
X software (Tree Star). A series of serially diluted CD34+
cells was prepared using TkSPD4 donor’s PBMCs by
combining the microbead-selected samples and the flow-
through population. The immunostaining and flow cy-
tometry analysis were performed in the same way as
described above.
a
b d
e
c
Fig. 1 Healthy donor-derived human-induced pluripotent stem cell (hiPSC) generation from non-mobilized peripheral blood (PB)-derived CD34+
hematopoietic stem and progenitor cells (HSPCs) using SeVdp(KOSM)-302L. a Schematic diagram illustrating the schedule of hiPSC generation. b
Percentages of cells expressing CD34, as assessed by FACS analysis of non-enriched peripheral blood mononuclear cells (PBMCs), a flow-through
population (flow-through), and the CD34+-selected cells (CD34+ cells). The results demonstrate significant enrichment of the CD34+ cells (up to
60.8%) after immunomagnetic bead selection. c Sequential images of a representative colony derived from SeVdp(KOSM)-302L-transduced CD34+
cells, showing a phase of initial proliferation (day 1–day 4), followed by the formation of spherical colony-like structures (day 5–day 11). Also
shown are images of typical hiPSC-like colonies that appeared during the subsequent expansion phase (day 17 and day 37). Magnified images
are shown in insets for clarity. P1 and P4 indicate passage 1 and passage 4, respectively. d Colony formation efficiency of each seeded cell type.
PBMCs, flow-through cells, and CD34+ cells were tested after infection with SeVdp(KOSM)-302L. Each bar represents the efficiency assessed in
each individual well. The mean efficiency values for PBMCs (0.17%), flow-through (0%), and CD34+ PBMCs (5.58%) are shown. e Fluorescent
images of live colonies stained with anti-TRA-1-60 antibody (red, top), anti-TRA-1-81 antibody (green, middle), or the CDy1 dye (red, bottom).
Nuclei were stained with Hoechst 33342 dye (blue)
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hiPSC generation
At day − 1, the CD34+-enriched cells were infected with
SeVdp(KOSM)-302L at a multiplicity of infection (MOI) of
3–7 (Fig. 1a). For the experiment shown in Additional file 5:
Figure S4, the CytoTune®-iPS2.0 (ID Pharma) was used
to infect CD34+-enriched cells at an MOI of > 1, > 3,
and > 6, based on the titer described in the instruction
manual (> 5.0 × 106 CIU/100 μL). After addition of
the viral vector, the cells were left at room
temperature for 2 h and then incubated overnight at
37 °C with 5% CO2. At day 0, the SeVdp(KOSM)-
302L-infected cells were seeded into iMatrix-511
(Nippi)-coated 6-well plates (TPP) with StemFit®
AK02N medium (REPROCELL) containing 10 μM Y-
27632 (Fig. 1a). At day 2, half the medium volume was
replaced with fresh StemFit AK02N medium, follow-
ing which the entire medium was changed on every 2
days until colony pickup. At days 8–14, individual col-
onies with an appropriate size of 250–500 μm in
diameter were picked up into iMatrix-511-coated 24-
well plates (TPP) containing StemFit AK02N medium
supplemented with 10 μM Y-27632 (Fig. 1a). At the
medium changes on every 2 days, small interfering
RNA (siRNA) treatment against SeVdp(KOSM)-302L
was performed 3 times using Lipofectamine™ RNAi-
MAX Transfection Reagent (Invitrogen) according to
the manufacturer’s instructions (Fig. 1a). The two siR-
NAs (siL527 and siL1913), used at 1.6 nM each, were
generated from the following single-stranded RNA ol-
igonucleotides (Fasmac): siL527-S, 5′-GGUUCAG-
CAUCAAAUAUGAAG-3′; siL527-AS, 5′-UCAU
AUUUGAUGCUGAACCAU-3′; siL1913-S, 5′-GGUC
CAGACAUGAAUUCAAAG-3′; and siL1913-AS, 5′-
UUGAAUUCAUGUCUGGACCAU-3′.
hiPSC expansion and maintenance culture for storage
For expansion and maintenance, hiPSCs were cultured
on iMatrix-511- or Vitronectin (VTN-N, Gibco)-coated
12- or 6-well plates in StemFit AK02N medium (with
iMatrix-511) or Essential 8™ medium (Gibco) (with
VTN-N) at 37 °C with 5% CO2. Daily medium change
was routinely performed. When passaged, the hiPSCs
were mechanically and enzymatically detached from the
plates using a scraper, 0.5× TrypLE™ Select (Gibco), 0.5
mM EDTA (Invitrogen), and/or Accutase® (Sigma), and
plated on fresh iMatrix-511- or VTN-N-coated plates in
the respective medium described above (containing 10
μM Y-27632). Before their use in the experiments, all
cells were confirmed to be mycoplasma-free, using the
MycoAlert™ Mycoplasma Detection Kit (Lonza) and
MycoAlert™ Assay Control Kit (Lonza). Luminescence
was measured with a GloMax® Explorer system (Pro-
mega). Images of hiPSC colonies were captured with a
Leica DMI3000B system and their processing was per-
formed using the ImageJ (NIH) or GNU Image Manipu-
lation Program 2.10 (GIMP2.10). Unless we had a
specific need, we generally selected ~ 12 colonies for the
subsequent expansion steps that lasted for another 4–5
weeks. The small-scale frozen stocks (2 tubes) of the 12
lines were initially generated as the backup stocks, with
the cells kept in the iMatrix-511/StemFit AK02N media
(Fig. 1a). Six lines were adapted to culture under the
VTN-N/Essential 8 conditions and finally stored as
large-scale frozen stocks (10 tubes), where ~ 2.0 × 106
cells per tube were cryopreserved in Bambanker for the
hiPSC banking.
RT-PCR verification of SeVdp(KOSM)-302L removal
Total RNA was isolated from the hiPSCs using the AllPrep
DNA/RNA Mini Kit (Qiagen), RNeasy® Mini Kit (Qiagen),
or Monarch® Total RNA Miniprep Kit (New England
Biolabs). Complementary DNA (cDNA) was synthesized
using the High-Capacity cDNA Reverse Transcription Kit
Table 2 Amounts of PB, PBMCs, and CD34+-enriched cells used
for reprogramming
Healthy donor
and patients
(hiPSC line)
Amounts of PB and
cryopreserved PBMCs
used for hiPSC generation
(% of live PBMCs after
thawing)
No. of CD34+-enriched
cells for transfection
Healthy (TkPP2) – 1.0 × 107 cells 15,000
SLE (TkSLE3) 8.8 mL 0.4 × 107 cells (33%) 13,000
SLE (TkSLE4) 18.4 mL 1.0 × 107 cells (50%) 16,000
SLE (TkSLE5) 7.5 mL 1.0 × 107 cells (71%) 39,375
PM (TkSPD3) 7.5 mL 0.5 × 107 cells (52%) 11,500
PM (TkSPD4) 4.2 mL 1.0 × 107 cells (61%) 12,5000
PM (TkSPD5) 8.8 mL 1.0 × 107 cells (38%) 14,000
X-CGD (TkSCG3) 13.1 mL 1.0 × 107 cells (53%) 24,700
X-CGD (TkSCG4) 8.5 mL 1.0 × 107 cells (56%) 9000
PID (TkSPR1) 5.3 mL 1.0 × 107 cells (76%) 18,000
PID (TkSPR2) 7.7 mL 1.0 × 107 cells (38%) 31,000
JIA (TkSCR1) 4.2 mL 1.0 × 107 cells (65%) 33,375
CMS (TkS42–1) 13.9 mL 1.0 × 107 cells (21%) 5500
MD (TkSmD1) 20.0 mL 1.0 × 107 cells (12%) 63,000
MD (TkSmD3) 4.7 mL 0.5 × 107 cells (56%) 55,000
KCS2 (TkSKCII2) 4.8 mL 0.5 × 107 cells (68%) 42,000
The amounts of peripheral blood (PB) and peripheral blood mononuclear cells
(PBMCs) used in the generation of these human induced pluripotent stem cell
(hiPSC) lines are listed. The PB volume shown here was calculated from the
corresponding PBMC numbers contained in each frozen vial (cryopreserved
PBMCs). The number of PBMCs represents the value before cryopreservation.
After thawing, a certain level of cell death occurs; % live PBMCs are thus
shown in parentheses, calculated by counting the actual number of living cells
recovered after thawing. The number of CD34+-enriched cells used for
SeVdp(KOSM)-302L transduction is also indicated
SLE systemic lupus erythematosus, PM polymyositis, X-CGD X-linked chronic
granulomatous disease, PID primary immunodeficiency, JIA juvenile idiopathic
arthritis, CMS congenital malformation syndrome, MD mitochondrial diabetes,
KCS2 Kenny-Caffey syndrome type 2
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(Applied Biosystems). The reverse transcription-polymerase
chain reaction (RT-PCR) assay for SeVdp(KOSM)-302L
cDNA was performed with TaKaRa Ex Taq® Hot Start
Version (TaKaRa). GAPDH was used as the internal
control. The PCR products were resolved on 2.5%
agarose gels. The primers used in this study are listed
in Additional file 1: Table S1.
In vitro differentiation of three germ layers
To analyze the capability of the hiPSCs to differentiate
into three germ layers, in vitro differentiation was per-
formed with the STEMdiff™ Trilineage Differentiation
Kit (STEM CELL Technologies) according to the manu-
facturer’s instructions.
Quantification of pluripotency and differentiation markers
with real-time PCR
cDNA was prepared as described above for quantifying
the pluripotency markers octamer-binding transcription
factor 4 (OCT4) and NANOG by multiplex TaqMan
real-time PCR, using the Eagle Taq Master Mix with
ROX (Roche). Universal probes #34 and #69 (Roche)
were used for labeling the OCT4 and NANOG products,
respectively. The Human G6PD Gene Assay (Roche) was
used for quantifying the reference gene. Because the uni-
versal probe #69 failed to be incorporated into the
NANOG transcripts of the TkPP2 lines owing to the
presence of a single nucleotide polymorphism, the SYBR
Green method was used with the Power SYBR Green
PCR Master Mix (Applied Biosystems) for these cell
lines only. The relative expression of OCT4 and NANOG
was evaluated with reference to their expression levels in
our standard hiPSC line TkDA3-4 previously established
from a healthy donor [41].
The gene expression of trilineage differentiation
markers was evaluated using a real-time PCR SYBR
Green method with the Power SYBR Green PCR Master
Mix (Applied Biosystems) or THUNDERBIRD® SYBR
qPCR Mix (Toyobo). The marker genes analyzed were
paired box 6 (PAX6), SRY-box 1 (SOX1), SRY-box 17
(SOX17), Foxhead box A2 (FOXA2), T-box transcription
factor T (or Brachyury) (TBXT), and neural cell adhesion
molecule (NCAM). G6PD was used as the reference
gene. The primers used in this analysis are listed in
Additional file 1: Table S1. All the real-time PCR
analyses were performed using a CFX96 C1000™ thermal
cycler (Bio-Rad). Relative expression was calculated by the
ΔΔCt method with CFX™ Manager software (Bio-Rad).
Detection of pluripotency characteristics with
immunostaining and chemical staining
Live hiPSC colonies were directly stained with the NL557-
conjugated anti-human TRA-1-60 antibody (NLLC4770R,
R&D Systems), the LN493-conjugated anti-human TRA-1-81
antibody (NLLC16581G, R&D Systems), or the fluor-
escent imaging probe CDy1 [42]. Fluorescence images
were captured with a Nikon Eclipse Ti microscope
system. Images were edited using ImageJ (NIH) or
GNU Image Manipulation Program 2.10 (GIMP2.10).
Karyotyping
hiPSCs were expanded in VTN-N-coated 25-cm2 flasks
(TPP) with Essential 8 medium. Standard G-banded
karyotyping was performed by the Chromosome Science
Laboratory or NIHON Gene Research Laboratories.
TCRγ gene rearrangement analysis
Genomic DNA was isolated using the AllPrep DNA/
RNA Mini Kit. Then, the rearrangement of the T cell re-
ceptor gamma (TCRγ) gene segment was analyzed using
the T Cell Receptor Gamma Gene Rearrangement Assay
Kit for Gel Detection (Invivoscribe) according to the
manufacturer’s instructions.
Flow cytometry analysis
Detailed information is provided in Additional file 2:
Supplemental Methods.
Results
Establishing hiPSC lines from healthy donor PB-derived
CD34+ HSPCs
We sought to establish an hiPSC generation method
capable of meeting the following requirements: (1) use
of non-mobilized PB cells, (2) compatibility with sched-
uled procedures, (3) integration-free culture, (4) absence
of immunoreceptor gene rearrangement, (5) high effi-
ciency, (6) cost-effectiveness, and (7) feeder-free condi-
tions. We finally achieved these goals with the protocol
summarized in Fig. 1a.
One example of a series of hiPSC generation processes
is shown in Fig. 1b–e. In this attempt, we started from
frozen healthy donor PBMCs (1.0 × 107 cells) that were
commercially available (Table 1). After thawing at day −
3, the PBMCs were kept overnight in an incubator under
cytokine-rich conditions, mainly in order to maximize
the recovery of viable HSPCs rather than to aim at cell
expansion. At day − 2, CD34+ cell enrichment was per-
formed using immunomagnetic beads, and the level of
enrichment was checked in an independent experiment.
The ~ 15,000 CD34+ cells enriched in this attempt
(Table 2) made up ~ 60% of the final selection product
(Fig. 1b). These cells were again kept overnight in a 96-
well plate under the cytokine-rich culture condition to
obtain only truly viable cells for the subsequent steps
(Fig. 1a). At day − 1, SeVdp(KSOM)-302L was added to
the cells at an MOI of 3 and the plates were incubated
overnight. After these 3-day procedures, the transduced
cells were seeded at various cell densities (i.e., 500, 1000,
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2000, and 4000 cells/well) onto iMatrix-511-coated 6-
well plates containing StemFit AK02N medium. No
more hematopoietic cytokines were needed beyond
day 0. After seeding, some adherent cells showed ini-
tial proliferation on days 1–3 and started forming
colony-like structures on days 4–6 (Fig. 1c). Once
formed, the growth of these spherical brown colonies
was rapid, with their size reaching > 200 μm at day 11
(Fig. 1c). On the basis of the number of colonies
counted at day 7, the colony formation efficiency was
calculated to be 5.58% per cell input (Fig. 1d and
Table 3), which was extremely high compared with
that of previous reports (< 1% in many cases) [43, 44].
These primary colonies were confirmed to be TRA-1-
60-positive and TRA-1-81-positive (Fig. 1e). They also
stained positively with CDy1 dye (Fig. 1e), demonstrat-
ing that their characteristics were compatible with
those of pluripotent colonies. When the non-enriched
PBMCs and flow-through samples (both containing
only a few CD34+ cells (Fig. 1b)) were used under the
same conditions, colony formation barely occurred
(Fig. 1d), suggesting that the CD34+ cells represented
a preferable target for highly efficient hiPSC gener-
ation in the SeVdp(KOSM)-302L reprogramming sys-
tem. The idea that the purified CD34+ cells are well-
suited to hiPSC establishment was later confirmed by
the additional experiment, the results of which showed
a strong positive correlation between the proportion
of CD34+ cells and the colony formation efficiencies
(Additional file 3: Figure S1).
To establish stable hiPSC lines, we tentatively per-
formed a random pickup of 10 colonies larger than
the 250-μm diameter on day 11. Their spherical shape
under feeder-free conditions allowed for an extremely
facile colony pickup procedure. We carried out siRNA
treatment against SeVdp-302L during the initial post-
pickup culture, with no colonies lost in the subse-
quent expansion phase. We divided each line into
two feeder-free conditions (i.e., iMatrix-511/StemFit
AK02N and VTN-N/Essential 8) and eventually estab-
lished all 10 lines as stable hiPSCs named TkPP2
(Fig. 1c and Table 3). The colonies of the TkPP2 lines
showed a typical hiPSC monolayer morphology (day 37,
Figs. 1c and 2f) and were stable in culture after their
recovery from cryopreservation, with their pluripotency
characteristics maintained (discussed below). This trial
demonstrated the high success rate of hiPSC generation
from non-mobilized PB samples with no need for extensive
expansion culture, allowing a rapid (5–6 weeks) and robust
protocol that is appropriate for the purpose of biobanking.
Table 3 Colony formation efficiencies and number of established lines
Healthy donor and patients
(hiPSC line)
Colony formation efficiencies
(No. of colonies/No. of seeded cells)
No. of colonies
per 1 mL blood
No. of lines
established
Recovery success
rate from frozen
stock (No. of lines
checked)
Healthy (TkPP2) 5.58% (781/14,000) – 10 100% (2)
SLE (TkSLE3) 2.61% (339/13,000) 38.5 12 100% (6)
SLE (TkSLE4) 0.08% (12/16,000) 0.65 4 100% (4)
SLE (TkSLE5) 3.26% (1283/39,375) 171.1 12 100% (6)
PM (TkSPD3) 1.67% (130/7750) 17.4 12 100% (5)
PM (TkSPD4) 3.17% (246/7750) 59.1 14 100% (3)
PM (TkSPD5) 0.10% (16/14,000) 1.8 12 100% (6)
X-CGD (TkSCG3) 0.29% (23/7750) 1.7 12 100% (6)
X-CGD (TkSCG4) 0.26% (23/9000) 2.7 12 100% (6)
PID (TkSPR1) 2.43% (438/18,000) 83.2 12 100% (5)
PID (TkSPR2) 2.50% (294/11,750) 38.1 12 100% (6)
JIA (TkSCR1) 1.59% (530/33,375) 126.7 11 100% (6)
CMS (TkS42–1) 0.34% (17/5000) 1.2 14 100% (6)
MD (TkSmD1) 1.09% (85/7800) 4.6 26 100% (7)
MD (TkSmD3) 1.09% (215/19,763) 45.9 36 100% (13)
KCS2 (TkSKCII2) 0.15% (43/27,750) 8.9 12 100% (2)
The colony formation efficiency of each seeded cell line and the estimated number of colonies per 1 mL of peripheral blood are shown. The ratios of the total
number of emerged primary colonies/the total number of seeded cells are indicated in parentheses. The number of human induced pluripotent stem cell (hiPSC)
lines established from each sample is also shown. The right-hand column shows the success rate of recovering lines from frozen stock, meaning that there were
no failures in the freeze–thaw process for all the established stocks tested
SLE Systemic lupus erythematosus, PM Polymyositis, X-CGD X-linked chronic granulomatous disease, PID Primary immunodeficiency, JIA Juvenile idiopathic
arthritis, CMS Congenital malformation syndrome, MD Mitochondrial diabetes, KCS2 Kenny-Caffey syndrome type 2
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Preparation of non-mobilized PB-derived CD34+ HSPCs
from patients
We next applied the established method to the generation
of patient-derived hiPSC lines. PB samples were obtained
from 15 patients of various ages (range 3–65 years) and
with different types of diseases (Table 1). Among these 15
patients, there were 3 cases of systemic lupus
erythematosus (SLE), 3 cases of polymyositis (PM), 2 cases
of X-linked chronic granulomatous disease (X-CGD), 2
cases of primary immunodeficiency (PID), 1 case of juvenile
idiopathic arthritis (JIA), 1 case of congenital malformation
syndrome (CMS), 2 cases of mitochondrial diabetes (MD),
and 1 case of Kenny-Caffey syndrome type 2 (KCS2)
(Table 1). The detailed information of their diseases and
a b
d
e
c
f
Fig. 2 Establishment of a panel of patient-derived human induced pluripotent stem cell (hiPSC) lines from non-mobilized peripheral blood-derived
CD34+ hematopoietic stem and progenitor cells (HSPCs) using SeVdp(KOSM)-302L. a Sequential images of representative primary colony growth
observed in the process of TkSLE5 (top) and TkSCR1 cell line establishment (bottom). b Live cell image of a CDy1 dye-stained (red) representative
primary colony obtained at day 13 in the course of TkSPR2 cell line generation. c Scatter plots indicating the colony formation efficiency of the seeded
cells (y-axis) and the estimated number of hiPSC colonies obtained from 1 mL of blood (x-axis) from 15 patients. d Table showing the failure rates in
the colony pickup step (top) and in the subsequent hiPSC expansion process (bottom). e Bar chart showing the step-by-step progress in establishing
hiPSC lines from the healthy donor (TkPP2) and 15 patients. For clarity, bars are uniquely colored for each passage number: P0 (passage 0) in blue, P1
(passage 1) in green, P2 (passage 2) in orange, and P3 (passage 3) in yellow. The gray line shows a typical time point (day 11) for colony pickup, but
the actual pickup dates varied between day 8 and day 14. f Images of the healthy donor (TkPP2)- and 15 patient-derived hiPSC lines cultured under
feeder-free conditions after establishment, showing a typical monolayered colony appearance
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causative genetic lesions were not provided for this report
since they will be reported in more detail by collaborators
elsewhere.
Using a gradient separation method, the PBMCs were
obtained within a day of collection of 20–40 mL of
fresh PB samples from the patients. In the JIA and
CMS cases, PBMC purification was performed 1 day
after PB collection owing to the need for long-distance
transport of the samples. The number of PBMCs ob-
tained ranged between ~ 1.0 × 107 and ~ 7.0 × 107 cells
(0.45 × 106 to 2.4 × 106 cells/mL). These were all cryo-
preserved in aliquots until the start of hiPSC generation
(Table 1). At day − 3, a vial containing 0.4 × 107, 0.5 × 107,
or 1.0 × 107 PBMCs was thawed for each hiPSC generation
attempt, upon which it was shown that ~ 24–88% of
PBMCs had been lost during the storage (Table 2). To
ensure the survival of CD34+ HSPCs after thawing, the
cells were kept overnight in EB medium containing six cy-
tokines. At day − 2, CD34+ cell enrichment was performed
as described for TkPP2 (Fig. 1a). The number of recovered
cells after enrichment varied significantly among the patient
samples, ranging from 5500 to 125,000 cells (Table 2).
However, we did not experience any unsuccessful cases
with these limited materials (median values; 21,350 cells).
Successful establishment of patient-derived hiPSC lines
According to the established protocol, we infected the
patient-derived CD34+-rich HSPCs with SeVdp(KOSM)-
302L at an MOI of 3–7 on day − 1 and plated all or a
part of them onto iMatrix-511-coated 6-well plates at
various cell densities (i.e., 250–20,000 cells/well). Similar
to the observations made with TkPP2 establishment, the
attached cells gradually formed spherically shaped brown
colonies containing pluripotent cells (Fig. 2a, b). The col-
ony formation efficiencies per seeded cells showed some
variation, with the average value being 1.38 ± 1.17% (mean
± SD) (Fig. 2c and Table 3). In 9 out of the 15 cases, the
efficiencies varied between 1.09% and 3.26%, which trans-
lated to yields of 4.6–127.7 colonies per 1 mL of PB (Fig. 2c
and Table 3). However, for the other 6 cases, the efficiency
values were between 0.08% and 0.34% per seeded cells,
translating to 0.65–8.9 colonies per 1 mL of PB (Fig. 2c
and Table 3). The lower efficiencies in the latter group
may be attributable to the putative low titer of the SeVdp(-
KOSM)-302L stock used for the period corresponding to
the establishment, because when tested later, it was
discovered that a higher MOI (i.e., 7 instead of 3) of
the same virus was needed to obtain efficiencies above
1%. Nevertheless, the hiPSC generation efficiencies
obtained with our method can be considered as being
markedly high, even when compared with a previous
report that showed an efficient reprogramming (~
0.02%) of non-mobilized PBMCs using SeVdp(KOSM)-
302L in similar feeder-free conditions [45].
Since all colonies that were randomly picked up led to
the successful establishment of TkPP2 lines as described
above, we performed colony pickup for the establishment
of the patient-derived hiPSC lines in a similar manner,
mostly on day 11 (based simply on observations under the
microscope). Consequently, out of 294 colonies picked up,
all but one (0.34% pickup failure) showed initial attach-
ment and growth, enabling subsequent expansion culture.
Once subjected to culture for stable hiPSC line establish-
ment, all 223 selected colonies proved eventually to be
expandable, leading to the completion of the freezing stor-
age (Fig. 2d). The progress of the establishment processes
was similar in all hiPSC lines (Fig. 2e). Furthermore, the
overall process was fast, as we were able to end the culture
for each line routinely within ~ 5–6 weeks with the stor-
age of a sufficient number of hiPSCs showing typical
pluripotent colonies (Fig. 2f). So far, we have not found
any cases where we failed to recover viable hiPSC colonies
from their frozen stocks (Table 3). Collectively, these re-
sults demonstrate that our method enables the scheduled
establishment of disease-specific hiPSC lines from patient
PB samples with a high success rate.
Confirmation of the transgene-free status and karyotypes
To confirm the removal of SeVdp(KOSM)-302L in the
established hiPSC lines, we performed RT-PCR analysis
for the presence of vector genome sequences. As shown
in Fig. 3a, the amplicons representing the residual exist-
ence of the SeV genome were infrequently found. This,
however, occurred generally when assessed at an early
passage before the initial storage. The same line showed
the disappearance of detectable SeV sequences consist-
ently with a few additional passages (Fig. 3a), most likely
due to the auto-erasable function equipped in the SeVdp-
302L system [16]. Most of the hiPSC lines tested were
shown to be transgene-free at the time of storage (81 out
of 88 lines, Fig. 3c). Karyotyping analysis has so far been
conducted for a few of the patient-derived hiPSC lines and
is ongoing for some others, showing mostly normal karyo-
types (Fig. 3b, c). Taken together, the results indicate that
our method is compatible with the measure to obtain
integration-free hiPSC lines with a normal karyotype.
Verification of a non-T lymphoid-cell origin for the hiPSCs
Despite the HSPC enrichment procedure, our target
PBMC populations were thought to contain a significant
amount of non-CD34+ cells, which should include lympho-
cytes and monocytes (Fig. 1b). hiPSCs derived from T or B
cells would retain the originally rearranged immunorecep-
tor genome, which may be undesirable for some studies.
We therefore investigated the lymphocyte-related genomic
rearrangement of the TCRγ locus, using PCR. The TCRγ
gene rearrangement was not detected in any of the 38 lines
examined (Fig. 4a, b). The corresponding rearrangement
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was detectable in the T lymphoid cell-derived hiPSC line
TkSST2-2, which we reported previously [46], confirming
the validity of this assay (Fig. 4a). As B cells were thought
to be extremely refractory to reprogramming in our
system, necessitating enhancement by the coexpression
of other factors (e.g., C/EBPα), an analysis of immuno-
globulin genes was not conducted [47, 48]. Although
the origin of monocytes cannot be excluded, these
results—taken together with the great enhancement in
generation efficiencies observed after CD34+ cell en-
richment—suggest that the hiPSC lines have likely been
derived from HSPCs (Fig. 1d).
Stable pluripotency and trilineage differentiation
capability
All hiPSC lines were in a stable pluripotent state in
culture, showing the retention of pluripotency character-
istics, i.e., positive staining with the antibodies for
c
b
a
Fig. 3 Assessment of SeVdp(KOSM)-302L removal and karyotypes. a Gel images showing representative assessment results for the removal of the
SeVdp(KOSM)-302L genomes obtained by RT-PCR. The image demonstrates no detection of SeVdp(KOSM)-302L amplicons in all 9 TkPP2 lines,
whereas it shows positive results in 4 out of 6 TkSCG4 lines (at passages 5–6). Residual SeVdp(KOSM)-302L was no longer detected in these 6
TkSCG4 lines when assessed a few passages later (additional culture). SeVdp(−), negative control (uninfected hiPSC); SeV(+), low-positive control
(hiPSC carrying low copies); SeV(++), high-positive control (hiPSC carrying high copies). GAPDH was used as the internal control. b Representative
G-banded karyotyping images for 3 TkPP2 lines and 3 TkSCG4 lines. c Summary of the assessments of SeVdp(KOSM)-302L removal and G-band
karyotypes. hiPSC, human induced pluripotent stem cells; N.D., not done
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TRA-1-60 or TRA-1-81 and the CDy1 dye (Fig. 5a). Ex-
pression of the marker genes OCT4 and NANOG was
quantified in the 85 hiPSC lines using RT-qPCR to ver-
ify their pluripotency features. As shown in Fig. 5b, c,
all the lines exhibited the expression of these genes,
demonstrating their pluripotent status. Expression of
these markers was also confirmed at a single cell level
when the samples were assessed by flow cytometry
analysis (Additional file 4: Figure S2).
Finally, we examined the capability of the 14 selected
hiPSC lines to differentiate into three germ layers with an
easy-to-use in vitro differentiation assay. After cultivation
under different conditions (i.e., either in an undifferenti-
ated state or with differentiation for an ectodermal, an
endodermal, or a mesodermal lineage), the hiPSC samples
were examined by RT-qPCR for their relative gene expres-
sion of three germ-layer markers: PAX6 and SOX1 (ecto-
derm), SOX17 and FOXA2 (endoderm), and TBXT and
NCAM (mesoderm). Selective upregulation patterns were
detectable for each marker gene in accordance with the
corresponding culture condition in all the hiPSC lines,
except for the ectodermal marker SOX1, the expression
levels of which were also high in the undifferentiated state
(Fig. 5d). Increased expression of lineage-markers was also
observed at a protein level in the differentiated TkPP2
samples by flow cytometry analysis, demonstrating the
utility of this in vitro differentiation assay system
(Additional file 5: Figure S3). These results confirmed
that the patient-derived hiPSC lines established by our
method could be stably maintained in a pluripotent cul-
ture and retain their trilineage differentiation capability,
both conditions of which are mandatory for these cell
lines to be truly valuable.
Discussion
Herein, we have described a rapid and simple method for
the robust establishment of transgene-free hiPSC lines using
the auto-erasable SeVdp(KOSM)-302L vector [16]. In this
method, we targeted non-mobilized PB-derived CD34+
HSPCs, with no need for cell mobilization and ex vivo ex-
pansion culture, and achieved highly efficient cell repro-
gramming under feeder-free conditions. Primary colonies
appeared rapidly, were easily manageable for pickup, and
showed robustness in the subsequent expansion steps. Using
this method, we succeeded in the scheduled establishment
of 223 hiPSC lines from PB samples obtained from 15 pa-
tients with 8 different diseases, generating a sufficient num-
ber of frozen stocks within 5–6 weeks. These hiPSC lines
showed consistent recovery from frozen stocks, a transgene-
free status, normal karyotypes, non-T cell derivation,
stable pluripotency, and trilineage differentiation cap-
ability. This method is therefore valuable to robustly
and efficiently generate patient hiPSC lines, allowing
ba
Fig. 4 Analysis of the T cell receptor gamma (TCRγ) gene locus rearrangement. a Electrophoretic images showing the results of detection analysis
for the specific TCRγ gene rearrangement, conducted using the T Cell Receptor Gamma Gene Rearrangement Assay kit for Gel Detection. Top:
analysis of 9 independent TkPP2 lines. Bottom: analysis of 9 patient-derived human induced pluripotent stem cell (hiPSC) lines (names are
indicated). NTC, non-template control. IVS-0009 and IVS-0000 are the monoclonal and polyclonal samples, respectively, provided as positive
controls in the kit. Another positive control used was TkSST2-2 (top panel), a monoclonal T cell-derived hiPSC line established previously in our
laboratory. Note that there are no single detectable bands in the test sample lanes. b Summary of the results of the TCRγ gene rearrangement
analysis. No positive results were seen in the tested samples (38 hiPSC lines in total)
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reductions in the cost, time, and workload for the en-
tire procedure, which is advantageous for biobanking.
In our hiPSC banking, PB samples were used because
they were easily collected from patients, with less
invasiveness than that of other sources. PB can also be held
at room temperature for ~ 48 h, and the derived PBMCs
can be cryopreserved for a long period [19], enabling long-
distance sample transport and scheduled hiPSC generation.
a b
d
c
Fig. 5 Pluripotency marker expression and trilineage differentiation capability confirmed in the established human induced pluripotent stem cell
(hiPSC) lines. a Fluorescent images of live colonies stained with anti-TRA-1-60 antibody (red, left), anti-TRA-1-81 antibody (green, middle), or the
CDy1 dye (red, right). Phase-contrast images are also shown in a side-by-side fashion for each picture. Scale bars indicate 200 μm. b Graph
demonstrating the quantification results of OCT4 and NANOG transcripts in the TkPP2 lines, assessed by RT-qPCR analysis. The relative expression
values for each gene, normalized to the level observed in the standard TkDA3-4 hiPSC sample, are shown. CD34+-enriched cells derived from the
TkPP2 donor sample were used as the negative control (CD34). c Scatter plot showing a comprehensive representation of the relative expression
values of OCT4 and NANOG in the 85 hiPSC lines examined. The results of 76 patient-derived hiPSCs are shown as light green plots. The results of
9 TkPP2 lines (same data in b) are shown in dark green for comparison. d Graphs showing the relative expression values of each marker gene
calculated by the ΔΔCt method with CFX™ Manager software. The plots (14 hiPSC lines) are colored according to the culture condition shown at
the bottom. “Undifferentiated” (green) represents hiPSC samples cultured in a pluripotent state. The other samples were cells cultured under
differentiation conditions, with each being directed for the corresponding lineage (ectodermal, endodermal, or mesodermal)
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In fact, we succeeded in generating hiPSCs from all 15
patient-derived PBMC samples that had been cryopre-
served for a few months to 1 year. Of note is that despite
the TkSCR1 and TkS42-1 PB samples required long-
distance transport of over 24 h, they still resulted in the es-
tablishment of hiPSC lines without any detectable loss of
generation efficiency (Table 3).
Among the hematopoietic cells, CD34+ HSPCs are
often the preferred target cells for reprogramming, as
they generally allow relatively highly efficient reprogram-
ming [17, 20, 49–51]. Although CD34+ HSPCs can be
collected from cord blood and bone marrow as well, PB
is the source most suitable for patient hiPSC banking, be-
cause of its general availability. Their scarcity, however, has
made it difficult to utilize PB-derived CD34+ cells as a regu-
lar target. To overcome this limitation, either mobilization
or ex vivo expansion culture or both have been adopted for
PB-derived HSPC-targeted reprogramming [22–25]. G-
CSF-based mobilization, however, is considered too invasive
for patient hiPSC generation. When non-mobilized PB
samples are used, many protocols include cultivation steps
with various combinations of cytokines to increase the tar-
get progenitor cells and thus the reprogramming efficiency
[19, 21, 26–28, 30–33, 35–37, 52–54]. After expansion
culture (typically 4–10 days), approximately 1.0 × 105 to 1.0
× 107 target cells are obtained and used for the reprogram-
ming studies. Considering these facts, it is a marked feature
that our protocol eliminates the need for both mobilization
and expansion culture (Fig. 1). At present, however, we
have not extensively tried to make the protocol completely
cytokine-free. After immunomagnetic enrichment, the re-
covery of CD34+-rich HSPCs should be expected to be very
limited because of their extremely small numbers in non-
mobilized PB samples. As we continue to use frozen
PBMCs for the scheduled hiPSC establishment, the ex-
pected yields would become even lower. We therefore in-
cluded into the culture medium 6 cytokines that favored
HSPC survival during the first 3 days. Although this treat-
ment did not lead to a massive expansion of cells, it was
nevertheless enough for successful hiPSC generation. It
should be noted that our culture scale was small, thus
limiting the required volume of medium (3 mL maximum
on day − 3, and only 200 μL for culturing CD34+-enriched
cells thereafter) and the total amounts of cytokines made
available. To cut the cost further, we may be able to modify
the cytokine-related steps in the future.
As the number of target cells was limited, our method
needed reprogramming efficiencies high enough to pro-
duce a sufficient number of pluripotent colonies. To
target this small number of cells (< 10,000 cells in some
cases), the use of episomal vectors that have shown util-
ity in many applications [5, 28] may not be feasible for
the reason of practicality. Viral vectors are advantageous
in this context; however, the current methods have
revealed low reprogramming efficiencies (< 1%), even
when using another type of SeV vector, and yielded some
non-expandable primary colonies [19, 24, 31, 34]. In
contrast, our method allowed the highly efficient gener-
ation of primary colonies (up to 5.58%) and, more im-
portantly, enabled high success rates in the establishment
of stable hiPSC lines with almost no fear of failure in the
subsequent expansion steps after random pickup (Figs. 1
and 2). The hiPSC lines established showed stable pluripo-
tency and trilineage differentiation capability (Fig. 5). We
thus concluded that the special combination of SeVdp(-
KOSM)-302L and non-mobilized PB-derived CD34+ cells
represented the best match, leading to the establishment of
the highly successful protocol. This report has further ex-
tended the utility of SeVdp(KOSM)-302L to hiPSC gener-
ation, which has been demonstrated with other human
cellular sources [45, 46, 55–59].
Besides its high efficiency, our protocol reduced the time
and workload required for the entire procedure (Figs 1 and
2). Overall, a sufficient number of hiPSCs for cryopreserved
stocks—which proved recoverable—were obtained within
5–6 weeks in all cases. More recently, we generally per-
formed colony pickup at day 8 and could end the entire es-
tablishment process by day 35 after seeding in many cases.
We speculated that the feeder-free condition using iMatrix-
511 (Laminin-511-E8 fragment) combined with the StemFit
AK02N medium might favor the rapid appearance of pri-
mary colonies and subsequent early cell growth, especially
due to its great potential in supporting single-cell survival
and firm cell adhesion to the plate [28, 60]. We also
adapted hiPSCs to Essential 8 medium on VTN-N-coated
plates in the late expansion phase for their cryopreservation
(Fig. 1). This latter culture could help in the distribution of
hiPSCs to other investigators, because we have found that
the hiPSCs in stock are compatible with various culture
conditions after thawing, irrespective of what culture sys-
tems other researchers use. The entire feeder-free protocol
also benefits researchers by reducing their workload, elim-
inating the S23need for feeder cell handling.
Currently, researchers prefer the use of hiPSCs that
are free of any genetic materials left behind after
reprogramming procedures, because the residual ex-
pression of transgenes is known to affect the differen-
tiation capability [61]. We had previously demonstrated
the generation of a series of hiPSC lines using an older
version of the non-auto-erasable Sendai virus vector
(SeVdp), which required routine siRNA treatment to
erase the SeV genome in the emerging hiPSCs [38–40].
Although we knew that SeVdp(KSOM)-302L was
equipped with an auto-erasable function, we carried
out siRNA treatment against SeVdp-302L to maximize
the removal of the viral genomes (see the “Methods”
section). Overall, the residual SeVdp-302L genome was
rarely detected. Even when some residual genomes
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were detected, they disappeared spontaneously with a
few additional cultures (Fig. 3). From these observa-
tions, we concluded that the auto-erasable function of
SeVdp-302L worked efficiently in our protocol in a
similar way as reported previously [16].
In this report, we described the successful establish-
ment of an initial series of 223 hiPSC lines, derived from
15 patients affected by 8 different diseases, which in-
cluded autoimmune diseases such as SLE and PD, im-
mune deficiencies exemplified by X-CGD, and other
diseases such as MD and KCS2 (Table 1). Recently,
Gomez Limia et al. [62] reported the successful gener-
ation of hiPSCs from a patient, using a very similar
method, where non-mobilized PB-derived CD34+ HSPCs
with no ex vivo expansion (probably from a fresh, un-
frozen sample) were reprogrammed to pluripotency
under feeder-free conditions using Geltrex with the SeV
vector (CytoTune® 2.0). When tested in our protocol,
the CytoTune®-iPS 2.0 also yielded primary hiPSC col-
onies with very high efficiencies at the given setting
(Additional file 6: Figure S4). Although still preliminary,
the use of Sendai virus vector systems may be consid-
ered commonly compatible with our protocol. By our
hands, cell line establishment is currently still ongoing,
and the panel of disease-specific hiPSCs is thus expand-
ing. Some of the hiPSC lines established in this study are
already being used for disease studies by our collabora-
tors and our research team, and the results will be re-
ported elsewhere in the near future. For example, we
have confirmed that neutrophilic cells differentiated
from the TkSCG3 and TkSCG4 lines, derived from X-
CGD patients, show severe defects in reactive oxygen
species production (data not shown), similar to another
X-CGD-iPSC line that we reported previously [39]. Such
findings indicate the applicability of the established
hiPSC lines to disease-modeling studies.
Conclusions
In summary, we have developed an improved feeder-
free method for establishing transgene-free hiPSC lines
from non-mobilized PB-derived CD34+ HSPCs, using
the auto-erasable SeVdp(KOSM)-302L. With this method,
we successfully established a panel of disease-specific
hiPSC lines from 15 patients with 8 different disease
types. The hiPSC generation was feasible with the use
of cryopreserved PBMCs, even after long-distance
transport of the sampled PB. This method rapidly gen-
erated expandable primary colonies with high effi-
ciency, resulting in the establishment of stable hiPSC
lines with almost no failure cases. We confirmed that
the hiPSC lines were suitable for use in disease model-
ing studies by showing their efficient transgene re-
moval, normal karyotypes, non-T cell origin, and stable
pluripotency and differentiation capability. Overall, this
method allows for the scheduled generation of a panel
of disease-specific hiPSC lines from patient-derived
non-mobilized PB samples in a cost-effective and time-
and labor-saving manner.
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